Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue
Concord Biotech Ltd · Investor Presentation · 28 Oct 2026, 1:51 am
Concord Biotech Reports Solid Q2FY27 Results, Approves 1:1 Bonus Issue Concord Biotech delivered strong consolidated performance for the period ended 30th Sep'26, with Q2FY27 revenue rising 25.1% YoY to ₹309.1 Cr, driven by broad-based demand and a 30% expansion in API sales to ₹250.2 Cr. EBITDA grew 18.0% YoY to ₹104.4 Cr (33.8% margin), while PAT climbed 10.3% YoY to ₹69.6 Cr. For H1FY27, revenue reached ₹566.6 Cr (+25.6% YoY) and PAT rose to ₹127.3 Cr (+19.0% YoY). The company approved a 1:1 bonus share issue, launched dermatology division Inspira, and secured ANDA approvals for Tofacitinib and MMF OS.
Original exchange filing (PDF)
More announcements from Concord Biotech Ltd
- Intimation of allotment of Bonus equity Shares · 05 Nov 2026
- Transcript of Q2 - FY27 Earnings call held on October 28, 2026 · 03 Nov 2026
- Earning Call Recording- For the Second Quarter and half year ended on September 30, 2026 · 29 Oct 2026
- Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 to be held on 03rd and 4th November, 2026. · 28 Oct 2026
- The Board of Directors at its meeting held on October 27, 2026 has fixed Wednesday, November 04, 2026 as record date for issuance of Bonus equity shares in the ratio of 1:1. · 28 Oct 2026
- Unaudited Standalone and Consolidated Financial Results for the second quarter and half year ended on September 30, 2026. · 28 Oct 2026
- Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 28 Oct 2026
- The Board of Directors of the Company, at its meeting held today i.e. Tuesday, October 27, 2026, has inter-alia considered and approved the Un-audited financial results for the quarter .... · 28 Oct 2026
